SCHEMBL6841337

SCHEMBL6841337

COCNC(=O)CSc1cccc(NC(=O)c2ccc(O)c(C(C)(C)C)c2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.45
KMT2A Q03164 3/20 0.45
MEN1 O00255 2/20 0.45
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
RAB9A P51151 3/20 0.41
TP53 P04637 2/20 0.41
TSHR P16473 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
LMNA P02545 2/20 0.41
TOP1 P11387 1/20 0.41
POLB P06746 3/20 0.41
NPC1 O15118 1/20 0.40
PPARG P37231 1/20 0.40
NCOA2 Q15596 1/20 0.40
NCOA1 Q15788 1/20 0.40
NCOA3 Q9Y6Q9 1/20 0.40
ANO1 Q5XXA6 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
KCNK9 Q9NPC2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6845355 0.88 TOP1 (0.49) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL6841338 0.83 SMN1; SMN2 (0.42) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL6841468 0.75 LMNA (0.46) MAPTKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL6844711 0.74 NR1H4 (0.53) MAPTKMT2AMEN1GAASMN1; SMN2
SCHEMBL6846730 0.72 MAPT (0.39) MAPTKMT2AMEN1RAB9ATP53
SCHEMBL6845356 0.71 TOP1 (0.49) MAPTKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL6846672 0.69 MEN1 (0.41) MAPTKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL18587755 0.67 HSP90AA1 (0.58) MAPTGAALMNAPOLBNR1H4
SCHEMBL20064060 0.66 RAB9A (0.62) MAPTKMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL6846568 0.65 GPR132 (0.55) KMT2AMEN1SMN1; SMN2RAB9ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BENDER STEVEN LEE (US) 2004-05-13 US disclosed
US-6635641-B2 For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis AGOURON PHARMACEUTICALS, INC. 2003-10-21 US disclosed
EP-1252146-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2002-10-30 EP disclosed
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use AGOURON PHARMACEUTICALS, INC. 2002-08-01 US disclosed
WO-2001053274-A1 AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2001-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092747-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA MAPT 899/4885KMT2A 3246/4885MEN1 4396/4885
US-20020103203-A1 Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use BRAF, CNKSR1, UACA MAPT 899/4885KMT2A 3246/4885MEN1 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.